PMID- 17168700
OWN - NLM
STAT- MEDLINE
DCOM- 20070228
LR  - 20190823
IS  - 0929-8673 (Print)
IS  - 0929-8673 (Linking)
VI  - 13
IP  - 26
DP  - 2006
TI  - Dendritic cell-based therapy as a multidisciplinary approach to cancer treatment: 
      present limitations and future scopes.
PG  - 3113-9
AB  - Existence of residual cancers and recurrence of cancers are two major limitations 
      of conventional therapies against cancers. A naturally-occurring defense system 
      against tumor may be established in cancer patients by induction of antitumor 
      immunity. Both polyvalent and tumor antigen-defined vaccines have been 
      administered to cancer patients to accomplish this. However, the efficacy of 
      these approaches is not promising. Dendritic cells (DCs) are regulator of the 
      immune system. Antigens loaded on DCs (antigen-pulsed DCs) are able to induce 
      immune responses when this can not be achieved by administration of antigens or 
      vaccines only. Tumor antigen-pulsed DCs are now used for treatment of patients 
      with cancers. But, it is unlikely that the present regimen of DC-based therapy 
      would be an independent anticancer therapeutic approach. However, the therapeutic 
      potentials of tumor antigen-pulsed DCs can be accentuated in cancer patients if 
      this immune therapy is performed as part of multidisciplinary therapeutic 
      approaches. In this review, we will describe about the concept and limitations of 
      the present regimen of tumor antigen-pulsed DC-based therapy in cancer patients. 
      We will further discuss how DC-based therapy can be applied as a 
      multidisciplinary approach to cancer treatment.
FAU - Fazle Akbar, S M
AU  - Fazle Akbar SM
AD  - Third Department of Internal Medicine, Ehime University School of Medicine, Toon 
      City, Ehime, Japan. akbar@m.ehime-u.ac.jp
FAU - Abe, Masanori
AU  - Abe M
FAU - Yoshida, Osamu
AU  - Yoshida O
FAU - Murakami, Hidehiro
AU  - Murakami H
FAU - Onji, Morikazu
AU  - Onji M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
RN  - 0 (Antigens, Neoplasm)
SB  - IM
MH  - Antigen Presentation
MH  - Antigens, Neoplasm
MH  - Dendritic Cells/immunology/*transplantation
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - Neoplasms/*therapy
RF  - 38
EDAT- 2006/12/16 09:00
MHDA- 2007/03/01 09:00
CRDT- 2006/12/16 09:00
PHST- 2006/12/16 09:00 [pubmed]
PHST- 2007/03/01 09:00 [medline]
PHST- 2006/12/16 09:00 [entrez]
AID - 10.2174/092986706778742882 [doi]
PST - ppublish
SO  - Curr Med Chem. 2006;13(26):3113-9. doi: 10.2174/092986706778742882.